MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Business/Financial News / Abiomed stock recovers some as company further questions critical Impella studies

Abiomed stock recovers some as company further questions critical Impella studies

November 19, 2019 By Chris Newmarker Leave a Comment

Abiomed's Impella 5.5 heart pumpShares of heart pump company Abiomed (NSDQ:ABMD) recovered a bit today — a day after the company’s stock took a 20% dive after two critical studies came out of American Heart Association’s Scientific Sessions.

The two separate studies — one led by researchers in St. Louis, the other out of San Francisco — suggested potentially serious complications involving the company’s Impella heart pumps. Abiomed officials today argued that the research was flawed for three reasons:

  • The data source had significant limitations, according to Abiomed. For example, it contained just a fraction of Impella patients and was unable to delineate between common adverse events.
  • The Impella patients in the research were much sicker and had greater baseline and procedural risks.
  • The analysis excluded the costliest intra-aortic balloon pump patients who were escalated to other therapies.

Abiomed shares were up 3.51% today, closing at $184.34 apiece.

The company noted that physicians have studied Impella for more than a decade — their work including FDA randomized controlled trials, FDA pre- and post-market studies and physician-led initiatives including the National Cardiogenic Shock Initiative (NCSI) study, the INOVA study and the Cardiogenic Shock Working Group.

“The real-world, contemporary experience of the National Cardiogenic Shock Initiative prospective clinical study consistently demonstrates improvements in survival and native heart recovery with best practices that include use of Impella,” Dr. William O’Neill, the principal investigator of NCSI and the medical director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit, said in an Abiomed news release.

“Payer databases, like the one used in the AHA analysis, are impossibly biased because the sicker patients will always go to Impella,” O’Neill said.

Filed Under: Business/Financial News, Cardiovascular, Featured, Wall Street Beat Tagged With: Abiomed

In case you missed it

  • Drug or device? FDA loses this argument for now
  • Aptar wins FDA clearance for ready-to-use seizure treatment device
  • Aurora Bio touts PET radiotracer data
  • Medical device excise tax would reduce R&D spending, report says
  • Proteus Digital Health restructuring amid reported funding woes
  • GE Healthcare partnering on regenerative tissue manufacturing
  • Schiller issues field safety notice for Tempus LS defibrillators
  • Report: 3M may sell off its drug-delivery business for $1 billion
  • Abbott issues field safety notice for Heartmate 3 LVAS power unit
  • Medtronic faces patent lawsuit over CoreValve tech
  • Orpyx launches sensory insoles with patient monitoring
  • Ortho devicemakers Hensler and Tobra face off in patent lawsuit
  • House bill asks CMS to cover breakthrough devices for Medicare patients
  • Empirical Spine completes enrollment in LimiFlex pivotal trial
  • MolecuLight wins FDA clearance for handheld imaging device
  • Medical device tax will cost 20,000 jobs, report says
  • W.L. Gore officials think they can spur insulin delivery system innovation

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS